Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
14 May 2018
E-002569-18
Question for written answer
to the Commission
Rule 130
Alfred Sant (S&D)

 Subject:  Commission estimates of the costs involved in health technology assessments
On 31 January 2018, the Commission published a legislative proposal aimed at strengthening EU cooperation on health technology assessment (HTA). In this regard:
1. Has the Commission modelled the average costs for a Member State to complete an individual HTA for a new medicine or technology?
2. Can the Commission confirm the number of HTAs undertaken in 2017?
3. On the basis of the answers to the above two questions, can the Commission estimate the total costs involved in undertaking an HTA for a new medicine across EU Member States and the potential cost savings from a unified approach to HTA as recommended in its proposal?
Last updated: 30 May 2018Legal notice